 Leigh Casadaban
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chemoembolization, Therapeutic | 5 | 2016 | 45 | 2.070 |
Why?
| | Liver Neoplasms | 7 | 2021 | 504 | 1.970 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 5 | 2015 | 36 | 1.620 |
Why?
| | Embolization, Therapeutic | 3 | 2022 | 178 | 1.450 |
Why?
| | Osteoarthritis, Knee | 2 | 2022 | 212 | 1.250 |
Why?
| | Colonic Neoplasms | 3 | 2017 | 210 | 1.050 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2016 | 210 | 0.980 |
Why?
| | End Stage Liver Disease | 2 | 2015 | 61 | 0.870 |
Why?
| | Pain Management | 2 | 2022 | 285 | 0.750 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2021 | 67 | 0.740 |
Why?
| | Arthralgia | 1 | 2020 | 46 | 0.690 |
Why?
| | Knee Joint | 1 | 2022 | 321 | 0.670 |
Why?
| | Leg | 1 | 2020 | 218 | 0.630 |
Why?
| | Ethiodized Oil | 2 | 2016 | 5 | 0.550 |
Why?
| | Liver Transplantation | 2 | 2014 | 693 | 0.550 |
Why?
| | Hepatic Artery | 2 | 2015 | 49 | 0.550 |
Why?
| | Esophageal and Gastric Varices | 1 | 2015 | 30 | 0.480 |
Why?
| | Hepatic Encephalopathy | 1 | 2014 | 19 | 0.470 |
Why?
| | Doxorubicin | 1 | 2016 | 283 | 0.470 |
Why?
| | Leukemia | 1 | 2017 | 208 | 0.470 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2014 | 4 | 0.460 |
Why?
| | Liver Function Tests | 1 | 2014 | 104 | 0.460 |
Why?
| | Biliary Tract | 1 | 2014 | 16 | 0.460 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2015 | 100 | 0.460 |
Why?
| | Hypertension, Portal | 1 | 2014 | 60 | 0.450 |
Why?
| | Emergencies | 1 | 2015 | 144 | 0.450 |
Why?
| | Jugular Veins | 1 | 2014 | 38 | 0.450 |
Why?
| | Adenocarcinoma | 2 | 2017 | 787 | 0.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1356 | 0.390 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 280 | 0.380 |
Why?
| | Thrombosis | 1 | 2013 | 293 | 0.340 |
Why?
| | Survival Rate | 5 | 2016 | 1634 | 0.320 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 115 | 0.320 |
Why?
| | Retrospective Studies | 11 | 2023 | 12504 | 0.310 |
Why?
| | Middle Aged | 14 | 2021 | 26552 | 0.300 |
Why?
| | Liver | 2 | 2018 | 1630 | 0.290 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 1872 | 0.280 |
Why?
| | Colectomy | 2 | 2017 | 87 | 0.260 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6296 | 0.250 |
Why?
| | Treatment Outcome | 8 | 2021 | 9006 | 0.250 |
Why?
| | Biomarkers | 1 | 2015 | 3389 | 0.240 |
Why?
| | Angiography | 3 | 2014 | 175 | 0.240 |
Why?
| | Chicago | 2 | 2014 | 45 | 0.240 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1159 | 0.230 |
Why?
| | Aged | 9 | 2021 | 18944 | 0.230 |
Why?
| | Humans | 20 | 2023 | 113531 | 0.230 |
Why?
| | Female | 16 | 2021 | 59115 | 0.220 |
Why?
| | Hyperaldosteronism | 1 | 2023 | 8 | 0.220 |
Why?
| | Male | 14 | 2018 | 55112 | 0.200 |
Why?
| | Arteries | 1 | 2022 | 244 | 0.180 |
Why?
| | Rabbits | 3 | 2016 | 713 | 0.170 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4384 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 332 | 0.150 |
Why?
| | Incidence | 2 | 2014 | 2310 | 0.150 |
Why?
| | Pain Measurement | 1 | 2020 | 440 | 0.150 |
Why?
| | Nitrogen Radioisotopes | 1 | 2018 | 5 | 0.150 |
Why?
| | Ablation Techniques | 1 | 2018 | 25 | 0.150 |
Why?
| | Propensity Score | 2 | 2016 | 225 | 0.150 |
Why?
| | Radiography, Interventional | 1 | 2018 | 105 | 0.140 |
Why?
| | Pain | 1 | 2022 | 699 | 0.140 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 260 | 0.130 |
Why?
| | In Situ Nick-End Labeling | 1 | 2016 | 117 | 0.130 |
Why?
| | Adult | 7 | 2021 | 30245 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2016 | 241 | 0.120 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2015 | 26 | 0.120 |
Why?
| | Illinois | 1 | 2015 | 37 | 0.120 |
Why?
| | Paracentesis | 1 | 2015 | 6 | 0.120 |
Why?
| | Prosthesis Fitting | 1 | 2015 | 13 | 0.120 |
Why?
| | Ascites | 1 | 2015 | 32 | 0.120 |
Why?
| | Hepatic Veins | 1 | 2015 | 29 | 0.120 |
Why?
| | Niacinamide | 1 | 2015 | 63 | 0.120 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 81 | 0.120 |
Why?
| | Dilatation | 1 | 2015 | 58 | 0.120 |
Why?
| | Pilot Projects | 2 | 2018 | 1356 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 925 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2014 | 24 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2269 | 0.110 |
Why?
| | Subtraction Technique | 1 | 2013 | 24 | 0.110 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 205 | 0.110 |
Why?
| | Angiogenesis Inhibitors | 1 | 2015 | 212 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1076 | 0.110 |
Why?
| | Risk Factors | 3 | 2015 | 8606 | 0.110 |
Why?
| | Vena Cava, Inferior | 1 | 2013 | 55 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2016 | 293 | 0.110 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 226 | 0.110 |
Why?
| | Vena Cava Filters | 1 | 2013 | 50 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2017 | 489 | 0.100 |
Why?
| | Device Removal | 1 | 2013 | 122 | 0.100 |
Why?
| | Acute Disease | 1 | 2015 | 885 | 0.100 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 136 | 0.100 |
Why?
| | Reoperation | 1 | 2014 | 505 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 984 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2015 | 737 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2013 | 142 | 0.100 |
Why?
| | Transcriptome | 1 | 2017 | 719 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1682 | 0.090 |
Why?
| | Endovascular Procedures | 1 | 2013 | 266 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2014 | 575 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1176 | 0.080 |
Why?
| | Prognosis | 1 | 2016 | 3318 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2014 | 2752 | 0.070 |
Why?
| | Disease Progression | 1 | 2014 | 2364 | 0.070 |
Why?
| | Cohort Studies | 1 | 2016 | 4880 | 0.070 |
Why?
| | Radiopharmaceuticals | 2 | 2018 | 158 | 0.060 |
Why?
| | Aldosterone | 1 | 2023 | 40 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2023 | 62 | 0.050 |
Why?
| | Animals | 3 | 2016 | 31162 | 0.040 |
Why?
| | Young Adult | 1 | 2014 | 10400 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 599 | 0.040 |
Why?
| | Microwaves | 1 | 2018 | 32 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 37 | 0.030 |
Why?
| | Fluorouracil | 1 | 2017 | 151 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2015 | 3470 | 0.030 |
Why?
| | Injections, Intra-Arterial | 1 | 2015 | 25 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 131 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2015 | 103 | 0.030 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 2014 | 6 | 0.030 |
Why?
| | Gamma Cameras | 1 | 2014 | 7 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 115 | 0.030 |
Why?
| | Yttrium Radioisotopes | 1 | 2014 | 51 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 227 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1203 | 0.030 |
Why?
| | Phlebography | 1 | 2013 | 35 | 0.030 |
Why?
| | Hindlimb | 1 | 2014 | 123 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2013 | 48 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2015 | 282 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 834 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 803 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1832 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 996 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1378 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 779 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 2993 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 2690 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2530 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 6189 | 0.020 |
Why?
| | United States | 1 | 2017 | 12137 | 0.010 |
Why?
|
|
Casadaban's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|